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Abstract
Extraintestinal manifestations (EIM) have become an impor-
tant source of morbidity and disability as well as an identified 
risk factor for an unfavorably course of disease in inflamma-
tory bowel diseases (IBD). Therefore, efforts have been put 
into a more global and interdisciplinary management of IBD 
patients in collaboration with rheumatologists, dermatolo-
gists, and ophthalmologists. A real therapeutic success has 
also been obtained with a more “systemic” IBD treatment 
associated with the development of monoclonal antibodies 
against TNF alpha and biological agents derived from the 
treatment of rheumatological disease (also called biological 
Disease-Modifying Antirheumatic Drugs). The prevalence of 
these EIM remains too low to undergo randomized con-
trolled trials with this specific focus and therefore the evi-
dence relies on case series and experts’ opinions, which low-
ers the level of evidence. After a careful review of the most 
recent literature, this paper aims to update the reader on the 
latest therapeutic management of IBD patients with EIM.
© 2020 S. Karger AG, Basel
Introduction
Extraintestinal manifestations (EIM) occur in about 
50% of inflammatory bowel disease (IBD) patients over 
the course of their disease. The prevalence has initially 
been rather underestimated [1], but more recent cohorts 
reported on the increasing importance of this phenome-
non [2].
The pathogenesis of the inflammation in IBD seems 
directly associated to it, as it acts beyond the gastrointes-
tinal tract, making it a systemic disease. The most fre-
quent EIM are distributed in 4 groups: musculoskeletal, 
ophthalmic, dermatological, and hepatobiliary disorders 
and could occur with or without a link to disease activity.
The development of EIM has a major impact on pa-
tient quality of life, increases the morbidity of these dis-
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eases, and disability of IBD patients. This manifestation 
can occur before, at, or after the diagnosis of IBD and, if 
present, should, in the presence of highly suggestive EIM, 
motivate the search for an underlying IBD, thereby re-
ducing the diagnostic delay. This has been nicely shown 
in the prospective Swiss IBD cohort study where about 
one-fourth of patients had EIM symptoms before IBD di-
agnosis was made [3].
Consequently, the caregivers have to take the patients 
with these manifestations more globally into consider-
ation when deciding on a specific treatment and seek for 
the help of a multidisciplinary management including, 
among others: rheumatologists, dermatologists, and oph-
thalmologists. In the specific group of primary sclerosing 
cholangitis (PSC) patients, a life-threatening risk is pres-
ent due to a much higher risk of development of neopla-
sia.
This review details the classification of the most com-
mon EIM, their characteristics, and treatment (Table 1). 
Extraintestinal complications of IBD, such as anemia, vi-
tamin deficiency, or urolithiasis and associated diseases, 
are beyond the scope of this review.
Rheumatological and Musculoskeletal 
Manifestations
Articular manifestation affects approximately 30% of 
patients with patients with IBD, more Crohn’s disease 
(CD) than ulcerative colitis (UC) [2, 4]. Peripheral joint 
pain is the most common EIM in patients with IBD; they 
are mostly noninflammatory and thus not comparable to 
inflammatory joint manifestations, which usually do not 
follow the course of disease and run independently [5]. 
IBD-associated axial arthritis is considered as a subgroup 
of the spondylarthropathies (SpA) by rheumatologists 
[6]. Interestingly, on the other hand, approximately 75% 
of patients with rheumatological disease will eventually 
develop digestives symptoms and even gut inflammation, 
but only about 7% will end up with an diagnosis of IBD 
[7] which is then considered as “extra-articular manifes-
tation” [8]. However, it is also possible that the real prev-
alence of coexistence of IBD and EIM is underestimated 
in some patients who develop initially an EIM and are 
treated with biologicals that could mask the digestive in-
volvement. The pathophysiological concept of the gut-
joint axis is advocated to underlie these manifestations. 
Indeed, genetic studies highly suggest a link with genes, 
which may be implied in both disease phenomenon [9–
12] and, that is, some receptors influencing bacterial im-
pact on the gut and joints inflammation, such as scaven-
ger receptor CD 163 on the macrophages surface, could 
also play a role [13, 14]. The idea of an aberrant homing 
of mucosal T cells and extraintestinal manifestations of 
IBD [15] has been also recently hypothesized in an inter-
esting publication from Dubinsky et al. [16] to explain the 
link between an obvious higher rate of EIM and the use 
of vedolizumab in UC. The authors hypothesized that the 
natural homing of active lymphocytes, which migrate 
from the blood into the lymphoid tissues, regulated by 
adhesion molecules and chemokines, is voluntarily im-
paired (basic mechanism of the drug). By that mean, 
more activated lymphocytes remain in the circulation, 
traffic to other organ system and probably aberrantly 
bind to inflamed synovial vessels. This aberrant homing 
to the joints does not depend on a4b7-MAdCAM-1 inter-
actions; however, several other adhesion molecules result 
(e.g., VAP-1) could act [17].
Table 1. Characteristics of the most frequent EIMs
EIM Parallel course  
of IBD
Separate course  
of IBD
May or may not  
parallel disease  
activity
Response to  
anti-TNF agents
Axial arthropathy ✓ +++
Peripheral arthropathy ✓ (Pauciarticular) ✓ (Polyarticular) ++
Erythema nodosum ✓ ++
Pyoderma gangrenosum ✓ ++
Oral aphtous ulcers ✓ ++
Episcleritis ✓ ++
Uveitis ✓ +++
Primary sclerosing cholangitis ✓ –
EIM, extraintestinal manifestation; IBD, inflammatory bowel diseases.
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IBD-Associated Axial and Peripheral Arthropathies
Peripheral arthropathies are described in the IBD lit-
erature as 2 types (1 and 2) [18] of which distinct charac-
teristics and behaviors presented in Table 2. IBD axial ar-
thropathy is considered as a subgroup of SpA, which are a 
chronic inflammatory disease of the axial skeleton and/or 
peripheral joints and also include ankylosing spondylitis 
(AS), psoriatic arthritis, reactive arthritis, and undifferen-
tiated SpA. Axial SpA occurs in 4–10% of CD patients, and 
making these diagnoses based on inflammatory back pain 
is a challenge for the gastroenterologist. A recent publica-
tion and review of > 250 patients from the Netherland con-
clude to an interesting and relevant referral algorithm for 
suspected axial spondyloarthritis in IBD patients. First, 
perform an anterior-posterior X-ray to search for a sacroi-
liitis (could be MRI in young patients to minimize radia-
tion and make earlier diagnosis), when positive refer the 
patient. However, when negative, check for other SpA fea-
tures such as inflammatory back pain, enthesitis, dactylitis, 
uveitis, positive family history, IBD, alternating buttock 
pain, psoriasis, arthritis, good response to nonsteroidal an-
ti-inflammatory drugs (NSAID), elevated ESR/CRP, and 
perform an HLA-B27 serology. If ≥4 SpA features or 2–3 
with positive HLA B-27, then referred (high probability of 
having axial SpA). Finally, patients with a positive HLA-
B27 test and the presence of ≤1 SpA feature should under-
go MRI [19]. This practical procedure is very close to the 
Assessment of SpondyloArthritis International Society cri-
teria use for the diagnosis, summarized in Table 3. 
Treatment of Arthropathies with Conventional 
Disease-Modifying Antirheumatic Drugs and Anti-
TNF Alpha Agents (Biological Disease-Modifying 
Antirheumatic Drugs)
Patients with IBD-associated SpA are commonly treat-
ed with physical therapy and NSAIDs to relieve pain, 
swelling, and stiffness. Frequently used with success by 
rheumatologists, NSAIDs represent a very controversial 
option for IBD patients [20, 21] as that they have been ac-
cused of inducing increased rate of flares, hospitalization, 
and complications [22, 23], which are not found in a re-
cent meta-analysis [24]. Therefore, NSAIDS should be 
used in the short term [25], or COX-2 inhibitors are an 
alternative option, as less negative data exist [26, 27], or 
paracetamol in case of residual pain or only minimal in-
flammation. Glucocorticoid injections directed to the lo-
cal site of musculoskeletal inflammation may also be con-
sidered. Patients with axial disease should not receive 
long-term treatment with systemic glucocorticoids, as 
stated in the European League Against Rheumatism rec-
ommendations [25, 28]. Alternative drugs for resistant 
peripheral arthritis only are the Disease-Modifying Anti-
rheumatic Drugs (DMARD) sulfasalazine and metho-
trexate. The use of these old drugs is mostly based on the 
recommendation for the treatment of AS [28]. The anti-
metabolite drug, methotrexate, is rather used in CD pa-
tients due to strongest evidence for the bowel disease and 
preferably for the indication of maintenance of a drug-
induced remission or in combination with biologics [29]. 
Table 2. Classification of enteropathic peripheral arthropathy associated with IBD. Adapted by S. Vavricka from the original article from 
[195]
Definition Type I (pauci-articular) Type II (polyarticular)
Prevalence CD, UC 6%, 3.6% 4%, 2.5%
Involvement Asymmetric, <5 joints Can be symmetric or asymmetric, may be erosive, 5 or more 
joints
Location Mainly large joints: knee > ankle > wrist > 
elbow > MCP > hip > shoulder
Mainly small joints: MCP > knees >> PIP > wrist > ankle > 
elbow > shoulder
Parallels disease activity Yes, similar to a reactive arthritis (e.g., post 
dysenteric)
No clinical course independent of IBD activity could  
predated the diagnosis of IBD
Natural course Self-limited episodes that last <10 weeks Persistent inflammation for months or even years
Associated With HLA-B27, B35, and HLA-DR 103 with 
high frequency of EN and uveitis.
With HLA-B44 with uveitis
IBD, inflammatory bowel diseases; CD, Crohn’s disease; UC, ulcerative colitis; MCP, metacarpophalangeal joint; PIP, proximal in-
terphalangeal joints; HLA, human leukocyte antigen; EN, erythema nodosum.
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Finally, biological agents are, for now > 20 years, the most 
efficient class of drugs to control all these rheumatologi-
cally manifestations, demonstrated in randomized clini-
cal trials [30] as well as historical cases series [31, 32]. The 
indication of the most commonly used anti-TNF agents, 
infliximab [33] and adalimumab [34, 35], is multiple, and 
the efficacy reach a good level and also drives a high num-
ber of indications in IBD patients, as demonstrated re-
cently in the Swiss IBD cohort study [36]. Paradoxal ar-
ticular manifestations are also frequently described in 
IBD patients under anti-TNF treatment and do not war-
rant the need of discontinuation of the medication [37]. 
Golimumab [38, 39] and Certolizumab [40] are also oth-
er TNF inhibitors to consider when treating rheumato-
logical EIM, in particular after a loss of response to inflix-
imab due to autoimmunity (antibodies against the drug) 
[41, 42]. Finally, Vedolizumab, a gut-specific anti-integ-
rin inhibitor, that blocks leucocytes migration to the in-
flammation site seems to influence mostly arthropathies 
linked to disease activity (Type II) in about 40% of the 
patients according to a small prospective French study 
[43], but also incidental inflammatory arthralgia/arthritis 
has been described in 14%, similarly to the publication 
from Mount Sinai Hospital [16]. The theoretical hypoth-
esis of the authors of the latter study is that Vedolizumab 
administration may lead to the trafficking of α4β7-
expressing lymphocytes to other organ systems and may 
predispose patients to develop EIMs with a parallel course 
to IBD.
Treatment of Arthropathies with Future IBD 
Therapies
Based on European League Against Rheumatism rec-
ommendations [28], biological DMARDs should be con-
sidered in patients with persistently high disease activity 
despite conventional treatment. Current practice is to 
start with TNF alpha therapy; however, most of IBD pa-
tients will eventually fail anti-TNF alpha agents due to 
either gastroenterological or rheumatological source of 
activity. That leads to the assumption that small mole-
cules, acting as targeted DMARDs, such as tofacitinib or 
other more specific medication like JAK 1 inhibitors 
(upadacitinib, folgitinib, baricitinib, peficitinib) will be 
used probably early in the disease course of these IBD pa-
tients with EIM [44]. Of note, Apremilast (Otezla®), 
which phase III trial was not conducted in UC, as well as 
ustekinumab (Stelara®), which should soon have indica-
tion in IBD, did not demonstrate efficacy in rheumatoid 
arthritis. Data are also disappointing in SpA patients 
treated with ustekinumab. Therefore, small molecules 
such as apremilast and kinase inhibitors are clearly enter-
ing the field as potential new treatment options. A de-
tailed overview is presented in Table 4 (with their refer-
ences) and commented below.
Tofacitinib, a pan-JAK inhibitor in doses of 5 and 10 
mg twice daily, has also been evaluated in phase II trials 
for clinical efficacy in patients with AS with promising 
results [45]; however, no further trials are planned for this 
Table 3. Inflammatory back pain criteria sets and mnemonic for assessment of axial spondyloarthritis, according 
to ASAS. Adapted from [196]
In patients with back pain ≥3 months and age at onset back pain <45 years (with/without peripheral manifesta-
tions)
(1) Sacroiliitis on imaging
–  Active (acute) inflammation on MRI highly suggestive of sacroliitis 
associated with SpA 




One or more SpA feature(s) 







– Good response to NSAIDS 
– Family history for SpA
Two or more SpA feature(s)
– HLA-B27 
– Elevated CRP
SpA, spondyloarthritis; ASAS, Assessment of SpondylArthritis international Society; NSAIDS, nonsteroidal 
anti-inflammatory drugs; CRP, C-reactive protein; CD, Crohn’s disease; UC, ulcerative colitis.
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Table 4. Current stand of JAK inhibitors (and other small molecules), IL-6, IL-12, IL-17 inhibitors tested in rheumatological diseases 
and IBD
Name Molecule CD UC Rheumatoid arthritis Ankylosing spondylitis Psoriasis/PsA
Tofacitinib
(1st gen.) CP690550
Pan-JAK inhibitor 🙁 Pilot, phase IIb study 
[136, 137]✓ Real life data ✓ OLE study [138]✓ Objective  
inflammation [139]
Approved 2018  
(Xeljanz®) [140, 141]
Approved 2012 [142]
as efficient as  
adalimumab [142]
✓Phase IIb study [45] 
but than discontinued
Approved for PsA, but 




JAK1 selective inihibitor ✓ Phase IIb study [145]✓ Effect on EIM [46]
Ongoing phase III
✓ Phase IIb study
[146, 147]
Ongoing phase III





✓ Phase IIb study [150]
Ongoing phase III
Ongoing phase III ✓ Phase III
= FINCH 3 study
✓ Phase II ✓ Phase II





No studies No studies Approved 2017
(Olumiant®)  
[151, 152]






JAK3 selective inhibitor No studies 🙁 Phase IIb [154] ✓ Phase III [155] No studies discontinued
Apremilast
NCT02289417
Phosphodiesterase 4 –  
inhibitor
No studies ✓ II [156, 157]/ 
will not undergo phase 
III
🙁 Phase II [158] ✓ Phase II [159]✓ Subgroup of phase  
III [160]
Approved 2014  
(Otezla®) [161–163]
Tocilizumab Anti-IL-6 receptor ✓ Pilot study [164] 🙁 1 case report of 
exacerbation [165]
1 case of improvement 
[166]
✓ Approved 2010 
(Actemra®)
[167] Higher risk of 
intestinal perforation 
[168]





✓ Approved 2016 
(Stelara®) [170]
✓ Phase III 🙁 Phase II [171] 🙁 Phase III ✓ Approved 2013 for 
PsA [172, 173]







✓ Phase IIb [176] No studies No studies No studies ✓ Phase III [177)
But withdrawal of FDA 
application due to 
severe adverse events.
Risankizumab  
ABBV 066,  
BI 6555066
Anti-IL 23 (p19 Inhibitor) ✓ Phase II [178)
ongoing phase III
Ongoing phase III No studies 🙁 Phase II [50] ✓ Approved 2019 for 
Psoriasis 




Anti-IL 23 (p19 Inhibitor) ✓ Phase IIa [181] No studies No studies No studies No studies
Guselkumab
CNTO1959
Anti-IL 23 (p19 Inhibitor) Ongoing phases II/III 
(galaxi)
Ongoing phases II/III 🙁 Phase II [171] ✓ Phase II ✓ Approved 2017 for 
psoriasis 




Anti-IL 23 (p19 inhibitor) ✓ Phase II [185] ✓ Phase II [186, 187] No studies No studies ✓ Phase II [188]
Brodalumab  
AMG 827/KHK4827
Anti-IL-17 RA 🙁🙁🙁 Worsen, 
phase IIa [189]
No studies No studies
(phase II canceled)





Anti-IL-17 A 🙁🙁🙁 Worsen, 
phase IIa [49]
No studies ✓ Phase III [192] ✓ Approved 2016 
(Cosentyx®) [193]
✓ Approved 2015 
(Cosentyx®) [194]
IL, interleukin; IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; PsA, psoriatic Arthritis.
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additional indication. Similarly, baricitinib and ruxoli-
tinib, which have a very similar spectrum of cytokine 
blockade to that of tofacitinib, have not been tested in IBD 
patients but probably have clinical potential. On reason 
could be the emergence of a “second generation” of JAK 
inhibitors for the treatment of immune-mediated diseas-
es that exert a selective blockade of JAK1 or JAK3 which, 
in theory, should have less risk of hematopoietic toxicity, 
an effect largely secondary to JAK2 inhibition. Promising 
data have been recently presented at the European 
Crohn’s and Colitis Organization congress in 220 upa-
dacitinib-treated CD patients showing a resolution of 
> 50% of the EIM with appropriate dosage of the drug 
compared to about 30% under placebo [46].
Biologics targeting interleukin (IL)-17 signaling have 
been approved for clinical use in AS. However, this mode 
of inhibition has demonstrated a deleterious effect with 
increased activity in CD patients in a phase III trial using 
secukinumab against placebo [47]. As plausible explana-
tion, a major alteration of intestinal barrier function as-
sociated with IL-17 inhibition and dysbiosis have been 
demonstrated in Mouse models [48, 49]. Targeting spe-
cifically the IL-23/12 pathway seems also quite disap-
pointing, as the anti-IL-23 biologic, risankizumab, failed 
to meet its primary endpoint in terms of efficacy in SpA 
[50] and ustekinumab, with a brighter spectrum, did not 
show enough efficacy in a phase III study in rheumatoid 
diseases [51]. Fingolimod and other, more selective, S1PR 
modulators are being developed for clinical use in IBD, 
but have, to our knowledge, not been tested in rheuma-
toid diseases.
Dermatological Manifestations
Up to 15% of IBD patients present with cutaneous EIM 
[2, 52]. These complications are usually diagnosed after 
excluding other skin disorders.
Erythema Nodosum
The frequency of erythema nodosum associated to 
IBD can reach up to 15% of CD and 10% of UC in some 
studies [52–54]. Erythema nodosum often coexists with 
eye and joint involvement, isolated colonic disease, and 
pyoderma gangrenosum. It presents with subcutaneous 
nodules, which are raised, tender, and red/violet and are 
typically located on the anterior part of the lower extrem-
ities. Rarely other body parts are involved [52]. Erythema 
nodosum is often self-limiting, and it depends on the ac-
tivity of the underlying disease [55]. 
In mild cases, topical corticosteroids, use of analgesics, 
compression stockings, and leg elevations were used [56]. 
Severe disease courses are treated with systemic cortico-
steroids, immunosuppressive therapies, or TNF antibod-
ies [57–61]. 
Pyoderma Gangrenosum
Pyoderma gangrenosum is a cutaneous EIM, which is 
more common in UC than in CD and affects women 
more frequently than men [61, 62]. Pyoderma gangreno-
sum often coexists with a familial history of UC, in pa-
tients with pancolitis, permanent stoma, eye involve-
ment, and erythema nodosum, and it is more prevalent in 
African-Americans [54]. The prevalence of pyoderma 
gangrenosum in IBD is 0.4–2% [1, 2, 53, 63, 64]. Most 
pyoderma gangrenosum lesions occur after a trauma 
(even years later), a phenomenon, which is known as 
pathergy. The lesions start as a small pustule, which 
spreads rapidly and develops deep purulent ulcers [65]. 
They mostly occur on extensor surfaces of the legs (shins) 
and adjacent to a postsurgical stoma, but can occur any-
where on the body, including the genitalia [66]. Pyoder-
ma gangrenosum may improve if the underlying IBD is 
treated successfully. Mild cases usually respond to local 
and topical therapy. Unusually, intralesional corticoste-
roid injections, moist treatment with hydroactive dress-
ings, and topical sodium cromoglycate are used [65, 67]. 
In more severe cases, systemic therapies such as oral sul-
fasalazine, dapsone, corticosteroids, and immunomodu-
lators (azathioprine, cyclophosphamide, cyclosporine, 
methotrexate, tacrolimus, and mycophenolate mofetil) 
are used [56, 65, 68, 69]. TNF-antibody therapy has show 
good therapeutic results in several case series and case re-
ports for infliximab [70–76] and for Adalimumab [77, 
78]. A success rate comparable to therapy of luminal IBD 
(> 60%) has been described in cases series of PG treated 
with Infliximab [70–76], but mostly linked to publication 
bias. For an overview on TNF-antibody therapies in EIM, 
please see reference [79]. 
Sweet Syndrome
Sweet syndrome, or acute febrile neutrophilic derma-
tosis, is a rare dermatologic manifestation associated with 
CD and UC [80, 81]. Sweet syndrome is not only associ-
ated with IBD but also can occur in other systemic dis-
eases and malignancies. Sweet’s syndrome manifests as 
tender or papulosquamous exanthema or nodules involv-
ing the arm, legs, trunk, hands, or face. Laboratory and 
histological features of Sweet’s syndrome are leukocytosis 
and a neutrophilic infiltrate. Patients present usually with 
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arthritis, fever, and ocular symptoms, mainly conjuncti-
vitis. Its association with IBD usually parallels the gastro-
intestinal disease activity but may precede the diagnosis 
of IBD [82]. IBD patients with Sweet’s syndrome respond 
to topical or systemic corticosteroid therapy [83] and heal 
without scarring. Metronidazole has been reported to be 
effective in one case report [82]. 
Oral Aphthous Lesions
Mainly in CD patients, the oral cavity of IBD patients 
can be affected. Besides periodontitis, aphthous lesions 
can occur. In severe cases, this is called pyostomatitis veg-
etans [2, 84–86]. Oral aphthous lesions usually follow the 
course of the underlying IBD. Aphthous lesions are typi-
cally located on the labial and buccal mucosa but may also 
affect the tongue and oropharynx. Pyostomatitis vegetans 
manifests as multiple pustular sometimes hemorrhagic 
eruptions anywhere on the oral mucosa with a cobble-
stone pattern. Antiseptic mouthwashes and topical ste-
roids are used as therapy [56, 87]. 
Hepatological Manifestations
Steatosis and other Frequent Liver Diseases 
The most frequent (1.5–55%) hepatic extraintestinal 
complications of IBD patients are the nonalcoholic fatty 
liver disease (from steatosis to nonalcoholic steato-hepa-
titis, or even cirrhosis) [88, 89]. A recent large screening 
study of IBD patients from Canada detected nonalcohol-
ic fatty liver disease in 33% of them, with 12% fibrosis 
[90]. Therefore, clinicians should be vigilant in screening 
patients with IBD for these diseases, as well as for chole-
cystolithiasis. A disturbed metabolism in IBD patients is 
causing these diseases to occur in concordance with rap-
id and large weight changes and steroid use. The preva-
lence of all liver disease in IBD is probably around 20% 
[91], among them drug-induced liver disease, vein throm-
bosis of the hepatic or portal, liver amyloidosis, and gran-
ulomatous hepatitis. Autoimmune hepatitis occurs also 
more frequently in IBD patients, associated with IBD dis-
eases or with PSC. 
Primary Sclerozing Cholangitis
PSC is a rare cholestatic liver disease characterized by 
progressive fibroinflammatory destruction of the intra- 
and/or extrahepatic biliary ducts of unknown origin [92]. 
Its diagnosis is based on a combination of typical 
symptoms and elevated serum markers of cholestasis 
(AP, γGT) not otherwise explained, characteristic bile 
duct changes in MRCP (or ERCP), and histological fea-
tures (if required due to a normal cholangiogram).
More than 70% of PSC patients have IBD (75% UC) in 
European population, whereas the opposite is only 
around 1–3% (5% for UC). This explains the European 
guidelines suggesting an endoscopy at diagnosis of PSC 
and then every 3–5 years [93]. This diseases’ association 
established since the sixties [94] exhibits a very specific 
IBD phenotype: a mildly active pancolitis with a right-to-
left inflammatory gradient associated with a greater inci-
dence of backwash ileitis and rectal sparing [95]. The evo-
lution of the liver disease is completely asymptomatic and 
can only be detected when the persistence of abnormal 
cholestatic pattern of the liver tests is further investigated 
with MRCP [96] and liver biopsy (for small-duct PSC) 
[25].
The hallmark of PSC associated with IBD is the higher 
risk of developing cancers and for 50% of them it will be 
the cause of death, in order of frequency and risks [97]: 
cholangiocarcinoma (161×) [98], pancreas (14×), colorec-
tal carcinoma (11×), gallbladder, and hepatocellular car-
cinoma. These data are based on a cohort study from 
 Sweden [99, 100], which had included 604 PSC patients 
from 10 hospital between 1970 and 1998, and the colorec-
tal cancer risk assessed by a meta-analysis [101] has also 
been confirmed by a French study [102] with 75 PSC-IBD 
patients during a > 40-year follow-up (1963–2006). 
Whereas colorectal cancer and gallbladder cancer [103], 
colonoscopy, ideally with chromoendoscopy, and ultra-
sound are recommended annually [25, 93, 104, 105], for 
cholangiocarcinoma annual surveillance using imaging 
(MRCP or US in a 12–24 month interval) and CA 19–9 is 
now being suggested [25, 105, 106] but has not reach the 
level of international recommendations and must there-
fore be considered with caution. For other hepatic cancer 
recent data from the Mayo clinic demonstrated also an 
impact of screening with imaging modalities [107]. 
As no efficient treatment exists and the course of dis-
ease is unpredictable, liver transplantation remains the 
final treatment of PSC-induced end-stage disease or he-
patocarcinoma. Unfortunately, the disease will eventu-
ally recurs on the graft (about 20% at 5 years). The con-
troversy concerning the ursodeoxycholic acid based on a 
placebo-controlled trial published in 1997 showing no 
survival benefit [108, 109] is not solved by the interna-
tional recommendations: the American association rec-
ommends against it [110], whereas the European associa-
tion let it open to the discretion of the physician [25, 111]. 
In real practice, most experts suggest a dosage of 15 mg/
kg [106]. There is a need for a better understanding of the 
Juillerat/Manz/Sauter/Zeitz/VavrickaDigestion8
DOI: 10.1159/000502816
mechanistical cause, and new more relevant clinical end-
points are [112] for incoming studies on new agents. One 
part of the solution could potentially come through the 
modulation of the microbiome and or bile acids, as it is 
now considered as part of the etiopathogenesis of this dis-
ease [113, 114]. In example, oral vancomycin has been 
tested in a small cohort of children with a substantial ben-
efit; however, a long-term use remains questionable [105]. 
The finding of aberrant expression of gut-restricted re-
ceptors for the adhesion molecule, such as α4β7, within 
the liver leads to a new hope when using the α4β7 mono-
clonal antibody, vedolizumab. The most recent data with 
an only 12-month follow-up showed only a slight impact 
on PSC-IBD. However, the lack of long-term follow-up 
endpoints such as end-stage liver disease, transplanta-
tion, and mortality could not be assessed [114]. 
Associated symptoms, such as pruritus, fatigue, and 
metabolic bone disease linked to PSC, need to be ade-
quately managed by the physician. Cholestyramine (4 g 
once or twice daily) should be started and, if unsuccessful, 
rifampicin, sertraline, and naltrexone are good alterna-
tives. Calcium and vitamin D intake should be optimized 
and associated with enough physical exercise. Bone den-
sitometry should be performed every 2–3 years and in 
cases of significant finding (osteopenia/porosis) an ap-
propriate bisphosphonate treatment initiated. Advanced 
stage disease leads to recurrent bacterial cholangitis as 
well as additional burden of a secondary biliary cirrhosis. 
Endoscopic treatments have some relevance has recently 
summarized in European Guidelines with balloon dila-
tion rather than stents which induce more complications 
[25, 93]. However, the frequency of these interventions 
should be balanced with the risk of being iatrogenic.
Ophthalmological Manifestations
Up to 2–5% of patients with IBD suffer from ocular 
manifestations, which include episcleritis and uveitis [55, 
84, 115]. CD patients present more often with ocular 
manifestations (3.5–6.3%) than UC patients (1.6–4.6%) 
[2, 52, 55, 115–117]. Patients aged over 40 years have 
more likely iritis/uveitis than those aged < 40 years [118].
Episcleritis and Scleritis
Episcleritis is defined as a painless hyperemia of the 
conjunctiva and sclera. Episcleritis is not associated with 
changes of the visus. CD patients present more often with 
episcleritis than UC patients [119]. Since episcleritis often 
parallels the underlying IBD, it does not need a specific 
therapy other than treating the underlying IBD. Scleritis 
on the other hand affects the deeper layers of the eye. Pa-
tients present with severe ocular pain and tenderness to 
palpation [120]. Scleritis can cause changes of the visus. 
Early diagnosis is therefore pivotal. If not treated, severe 
complications such as scleromalacia, retinal detachment, 
or optic nerve swelling may occur. It is therefore manda-
tory to start early and aggressive therapy. Disease-specif-
ic treatment and topical steroid therapy usually provide 
prompt relief of symptoms. In case of impairment of vi-
sion, the presence of scleritis must be suspected, and 
prompt referral to an ophthalmologist is mandatory to 
avoid vision loss.
Uveitis
Uveitis is less common than episcleritis and occurs in 
0.5–3% of patients with IBD. Anterior uveitis is the most 
common ocular manifestations of IBD. Uveitis is divided 
into 4 different manifestations: (i) anterior uveitis with a 
main site of inflammation in the anterior chamber, (ii) 
intermediate uveitis, where the inflammation is primary 
in the vitreous region, (iii) posterior uveitis, where retina 
and chorea are primarily involved, and (iv) panuveitis 
with its primary site of inflammation including anterior 
chamber, vitreous, retina, and choroid. The activity of 
uveitis is independent of the underlying IBD activity. Pa-
tients usually complain of pain and in case of iritis (ante-
rior uveitis) of photophobia, red eye, blurred vision, and 
floaters (mooches volantes). A small number of treatment 
options in IBD patients suffering from uveitis have been 
published [121–128]. Prompt diagnosis and treatment 
with topical and systemic corticosteroids is necessary to 
prevent progression to blindness. Steroid refractory cases 
are treated with cyclosporine A. Successful use of inflix-
imab for IBD-associated uveitis was demonstrated in a 
CD patient with uveitis and sacroiliitis [128]. 
Other Rare EIM
Other rare EIM of IBD have been described in the oth-
er organs. Their management is more disease specific and 
will not be detailed here. Neurological EIM are mostly 
peripheral neuropathy [129], whereas central demyelin-
ating diseases have been shown as well [130]. Pulmonary 
involvement exists with reports involving different parts 
of the bronchial tree from the glottis to small airways. In 
particular, interstitial pneumonitis has been suggested 
20–55% of IBD patients [131], the most frequent remain-
ing drug induced (5-ASA compounds, methotrexate, or 
anti-TNF alpha agents) [132] and infections. IBD patients 
are at increased risk of cardiovascular events (mainly ve-
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nous and arterial thromboembolism, myocardial infarc-
tion) which are more linked to the chronic inflammatory 
pattern of the disease and less to very rare associated car-
diovascular diseases [25, 133]. Finally, pancreatitis associ-
ated with IBD could also be considered as EIM after in-
clusion of biliary pancreatitis, drug-induced (i.e., azathio-
prine, amino salicylates) or autoimmune cause [134, 135]. 
Discussion and Conclusion
In the present review, we illustrate an update on the 
management of EIM of IBD patients. Whereas no new ef-
fective treatments has been identified so far for treatment 
of PSC but a high importance of performing cancer sur-
veillance, on the other hand, a bench of new molecules 
will emerge with an overlapping effect on gastrointestinal 
and rheumatological diseases. This later constellation is 
also linked to uveitis, which suggested that this EIM will 
probably also be improved by these therapies. The future 
is of the management of EIM remains bright and the un-
derstanding of their management is central to the gastro-
enterologist as it occurs in almost half of IBD patients and 
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